Glaucocalyxin A sensitizes ovarian cancer cells to PARP inhibitors by inducing DNA damage

CCNE1 overexpression drives a cGAS-STING-dependent interferon response and sensitizes HRD-positive ovarian cancer to immune checkpoint blockade.
Xueling Wang, Tian Chen, Zehua Wang +6
Journal for immunotherapy of cancer14 Oct 2026Peer-reviewedCC BY-NCFull textObstetrics, gynaecology & paediatricsEurope PMC
ERG inhibition selectively sensitizes ERG-positive prostate cancer to radiation through DNA repair vulnerabilities and enhances response to androgen receptor inhibitors.
Ayham Moustafa, Mohamed E Elsesy, Bente Siebels +14
Journal of experimental & clinical cancer research : CR23 Oct 2026Peer-reviewedCC BYFull textOncologyEurope PMCDOAJ
1105 HER3 inhibition sensitizes metastatic colorectal and pancreatic cancer to immunotherapy
Rui Wang, Elizabeth Bryson, Chao Wei +3
Journal for ImmunoTherapy of Cancer7 Nov 2026Peer-reviewedCC BYFull textOncologyDOAJ
The Smac mimetic drug Xevinapant sensitizes triple negative breast cancer to radiotherapy-induced cell death in a TNFα dependent manner
M. D. Faye, J. Lafontaine, P. Wong +1
bioRxiv29 Sep 2026PreprintAll rights reservedFull textOncologybioRxiv
Curcumin Sensitizes Colorectal Cancer Cells to TRAIL-Mediated Apoptosis
Erika Rimondi, Marta Manfredini, Francesca Nigro +5
International Journal of Molecular Sciences23 Oct 2026Peer-reviewedCC BY 4.0General medicineCrossref

Cite

BibTeX

@article{anon2026glaucocalyxin,
  title = {{Glaucocalyxin A sensitizes ovarian cancer cells to PARP inhibitors by inducing DNA damage}},
  journal = {Translational cancer research},
  year = {2026},
  month = aug,
  url = {https://europepmc.org/article/PMC/PMC13657847},
  note = {CC BY-NC-ND},
}

RIS

TY  - JOUR
TI  - Glaucocalyxin A sensitizes ovarian cancer cells to PARP inhibitors by inducing DNA damage
PY  - 2026
DA  - 2026/08/14
JO  - Translational cancer research
UR  - https://europepmc.org/article/PMC/PMC13657847
SN  - 2218-676X
ER  -

Related

Cite